BRIEF-Firebrick Pharma Announces License Agreement For Singapore, Malaysia, Brunei, Mauritius
Reuters
Aug 26
BRIEF-Firebrick Pharma Announces License Agreement For Singapore, Malaysia, Brunei, Mauritius
Aug 26 (Reuters) - Firebrick Pharma Ltd FRE.AX:
LICENSE AGREEMENT FOR SINGAPORE, MALAYSIA, BRUNEI, MAURITIUS
NEW AGREEMENT EXPECTED TO SIGNIFICANTLY REDUCE FIREBRICK'S MARKETING EXPENSES IN FY26
INNORINI APPOINTED EXCLUSIVE LICENSEE FOR NASODINE PRODUCTS IN SINGAPORE, MALAYSIA, BRUNEI AND MAURITIUS
Further company coverage: FRE.AX
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.